En 7 modules vidéos de 30 minutes, 7 spécialistes de l'EHESP vous proposent de découvrir le fonctionnement du système de santé et les concepts essentiels qui fondent les politiques et les modes de financement du secteur de la santé.
The US lags behind other regulated markets, particularly the European Union, in terms of biosimilar competition. However, this is about to change soon, as there are at least 14 expensive biotech drugs that will now face generic competition from drug makers who want to sell copycat versions at a lower price. This is expected to lead to a reduction in health-spending costs.
Biosimilars—Who Will Be The First and How?
“The Patient Protection and Affordable Care Act” of 2010 included the “Biological Price Competition and Innovation Act.” The Affordable Care act incorporated a clause that gave the FDA leeway to develop biosimilar approval protocols. The Food and Drug Administration (FDA) is still cranking out these guidelines but as of now, it hasn’t said no to biosimilar applications. The agency accepted its first biosimilar application last week despite the fact that there were no concrete guidelines in place for such approvals.
Novartis AG (ADR) (NVS) was the first company to file for an. The company wants to sell a biosimilar to Amgen, Inc.'s (AMGN) biotech cancer drug Neupogen, which brought in sales of $1.4 billion last year. Novartis may expect an approval for its application in March. The second biosimilar expected to receive US approval is Johnson & Johnson’s (JNJ) arthritis drug Remicade, made by South Korean generic company- Celltrion. The company had filed for approval in August.
Express Scripts Holding Company (ESRX) expects Amgen’s Epogen – for anemia caused by chronic kidney disease – and Roche Holding Ltd.’s (ADR) (RHHBY) bestseller Rituxan – for rheumatoid arthritis and certain blood cancers – to also receive stiff competition from some of the biosimilars expected to enter the market soon.
The Generic Pharmaceutical Association estimates that patients combined saved $239 billion last year by buying cheap generics of drugs whose patents had expired. Up until recently, biotech treatments, which were made from living cells, couldn't be accurately copied. Now, extensive research and development in biotechnology drugs has made it possible for their imitations to be developed. Cost-saving estimates for using generics will run up to $250 billion by 2024, according to some estimates.
La technologie RFID a eu un impact significatif sur l'industrie mondiale de la santé. L'adoption de systèmes de suivi RFID a été utile dans la réduction des efforts et des erreurs humaines dans la maintenance et le contrôle de la gestion d'inventaire, mais aussi dans l’amélioration de la sécurité du patient et la qualité des prestations.
L'association Les P'tits doudous de l'Hôpital sud, à Rennes, a lancé une application sur tablette pour aider les jeunes patients à combattre leur anxiété avant (RT @dmdsante: Une #appli anti-#stress préopératoire pour #enfants @ouestfrancefr...
PARIS, 15 septembre 2014 (TICsanté) - Le Conseil d'Etat suggère d'élargir l'utilisation du numéro de sécurité sociale aux domaines de la santé et de la recherche médicale, dans son étude annuelle présentée mardi dernier, recensant 50 propositions...
LE PLUS. Ce mardi 9 septembre, Apple a présenté ses deux nouveaux iPhone 6 ainsi que la montre connectée Apple Watch. Si parmi les petites révolutions, on retient l'arrivée du paiement sans contact, on ne peut pas passer à côté de Health et du HealthKit, l'application santé et le carnet de santé numérique de la pomme... dont Violaine des Courières se méfie.
Everyone involved in the healthcare value chain saw substantial industry shift during the start of 2014. Now, as the third quarter of the year gets underway, the industry continues to evolve with some chief changes and advancements rising to the top.
What are trending in the field of healthcare as we approach the remainder of 2014? Here are seven trends that will continue to directly affect the healthcare industry for the rest of the year and beyond.
Providers and industry followers, keep an eye on these trends as you can use these to strengthen your company’s future vision and gauge short-term tactical direction.
Recent data from the CDC has indicated that 50% of Americans are taking one prescription drug, and 10% are on 4 or more prescribed medications as well. Taking into consideration the aging population and the movement towards primary prevention with medications, it is likely a larger shift will occur in the next decade.
Coupled with this is the increasingly large role of social media in the daily lives of the social schema of many Americans — and we may have a new form of Drug Surveillance. It comes as no surprise that many patients report their daily status of health online, and include their experiences with their medications as well. But recent data has come out from researchers at Boston Children’s Hospital that Twitter alone could be a treasure trove of data.
Traditionally, adverse drug effects could be reported to the FDA through their Adverse Event Reporting System (FAERS). From this, monitoring post clinical trials can be conducted for any issues that may arise. Many medications have been adjusted or withdrawn from the market based on unseen side effects on patients.
But Friefield and colleague’s recent study in Drug Safety demonstrated that patients are increasingly reporting their side effects via Twitter. Utilizing a semi-automated process to identify 23 drug products on Twitter, approximately 7 million tweets were assessed, with 60,000 evaluated, producing 4,400 identified. Many of the events related to side effects from drugs and how they were responding to therapy.
Another recent study by White and colleague’s in JAMIA also highlighted the use of social media in drug safety analysis. The researchers have highlighted the growing use of social media as a low-cost monitoring tool for federal agencies and drug manufacturers to utilize.
While these studies are sure to spark great interest in the use of social media as a new method to collect post-market safety data, there may be some shortcomings to consider.
A l’occasion de l’Université d’été de la e-santé, le Dr Vincent Varlet, président d’Isidore santé, directeur exécutif des services marketing et communication de Novartis, dévoile les résultats d’une enquête menée en partenariat entre Isidore, Vidal, Egora, les laboratoires Expansciences et IDS Santé auprès des professionnels de santé “Les applications santé et vous”1. Au-delà des chiffres, pour le Dr Varlet, le constat est sans appel : “Si les médecins sont devenus utilisateurs d’applications mobiles de santé pour leur pratique, ils ne se sont pas encore tournés vers les applis patients. La fracture digitale entre les professionnels de santé et les patients risque de devenir une réalité si la France ne rattrape pas son retard en ce domaine”
As it does every year, analyst firm Gartner updated its famous Hype Cycle for Emerging Technologies this summer and, according to the firm, “mobile health monitoring” is approaching the bottom of the so-called “trough of disillusionment”.